Product
Luveltamab
Aliases
Luvelta, luveltamab tazevibulin, Luveltamab tazevibulin, STRO-002
Name
Luveltamab tazevibulin
Target
FolRα
FDA Approved
No
Ema approved
Status
0
1 clinical trial
1 drug
1 abstract
4 indications
Indication
Ovarian CancerIndication
Fallopian tube cancerIndication
Primary Peritoneal CancerIndication
Platinum-resistant Ovarian CancerDrug
LuveltamabClinical trial
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)Status: Recruiting, Estimated PCD: 2025-09-01
Abstract
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.Org: Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, The Ohio State University James Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University, University of Chicago,